New hope for advanced bile duct cancer: liver transplant after targeted radiation
NCT ID NCT06910722
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a liver transplant after a combination of targeted internal radiation (SIRT with Yttrium-90) and chemotherapy can improve 3-year survival in people with locally advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be surgically removed. The trial plans to enroll 36 participants in France. The main goal is to see if this strategy helps patients live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Yttrium-90 (radioactive beads) and chemotherapy
- What this could lead to
- If successful, this could offer a potential treatment path for people with advanced bile duct cancer that cannot be surgically removed, possibly improving long-term survival.
- What could go wrong
- This is a small, early-phase study with only 36 participants. The treatment is complex and carries risks from radiation, chemotherapy, and transplant surgery. It may not work for everyone or may not be widely available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beaujon
RECRUITINGClichy-sous-Bois, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action antibody boost chemo against bile duct cancer?
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?